Psychedelics cause a trip that lasts for 5-12 hours. Most people know psychoactive compounds such as Psilocybin as a recreational drug; however, the team of Bright Minds Biosciences has recognized and presented its therapeutic use as well.

With credited chemists such as Dr. Alan Kozikowski, Bright Minds Bio is determined to bring forward the next-generation treatment for brain health disorders.

After 1990, when doctors approved SSRIs as a possible treatment for neurological illnesses, there has been very little progress in treating people who suffer from neurological and neuropsychiatric illnesses.

Youngsters have a hard time getting treated for mental illnesses such as depression, anxiety, and even epilepsy. It happens due to economic as well as environmental problems.

Our biotechnology company has acknowledged such concerns and is focused on bringing modified psychoactive drugs to the market.

What Does Bright Minds Bio Do?

Incorporated in 2017, Bright Minds is the only biotechnology company focused on creating a treatment for brain health disorders.

• We have a team of expert drug developers, scientists, chemists, and professionals who create selective serotonin agents.

• These agonists are still at the Pre-Clinical Stage II

• Bright Minds Biosciences aims at bringing a revolution in the market by making the world aware of the therapeutic effects of psychedelic drugs such as Psilocybin

• Our team studies 5-HT2 receptors responsible for neurological illnesses such as epilepsy, MDD, PTSD, Dementia, Parkinson’s, etc.

• After studying receptors and how they function, the professionals modify/re-design the molecules of psychoactive compounds

• The re-designed molecules are prepared such that the actual ‘trip’ time becomes as low as 30 minutes

• Some of our pipeline projects include agonists for 5-HT2A. 5-HT2B, 5-HT2A/C, 5-HT2C, and 5-HT2C/A

• All of the above receptors belong to the serotonergic system

• Hence, most of our agonists target to maintain the level of serotonin

Which Psychedelic Drug Is The First To Go For Clinical Trials

Our biotechnology company uses Magic Mushrooms due to its legalization in Canada in Aug’2017. Legalizing Psilocybin has opened several avenues in the form of pharmacological tools.

However, Bright Minds Bio is the only company with a team that is 100% dedicated to creating better forms of Psilocybin.

• Although scientists have found that mental health patients respond better to psychedelic drugs than age-old SSRIs, very little is being done to use psychoactive drugs commercially.

• Psilocybin is known to treat depression, and anxiety on a large scale, due to its property being an agonist to 5-HT2 class receptors.

• Like the commercialization of certain strains of cannabis, Bright Minds is trying to commercialize the distribution and use of certain molecular compounds of Psilocybin.

• Ranging from addiction to chronic pain, and even treating serious conditions like Pharmacoresistant Epilepsy our selective serotonin agents can treat almost every brain health disorder.

• Our drug designers create new designs by altering the existing molecular design of Psilocybin. These compounds then get tested by the National Institute of Health.

• To know what stage of clinical trials we are in, visit our website.